Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
University of Miami
Olema Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Fudan University
OHSU Knight Cancer Institute
The University of Texas Health Science Center at San Antonio
Fudan University
Peking Union Medical College
National Cancer Institute (NCI)
University of Chicago
National Cancer Institute (NCI)
PrECOG, LLC.
EMD Serono
Roswell Park Cancer Institute
Yale University
University of Southern California
University of Chicago